Sugi Predict

Sugi Predict / Compounds / SCHEMBL1984153

SCHEMBL1984153

SCHEMBL1984153

Cc1ccc2nc(-c3ccc(NC(=O)c4ccccc4)cc3)sc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 1/20 0.74
▸ MMP9 P14780 1/20 0.74
▸ MMP8 P22894 1/20 0.74
▸ MMP13 P45452 1/20 0.74
▸ SMN1; SMN2 Q16637 8/20 0.72
▸ MAPT P10636 8/20 0.72
▸ LMNA P02545 2/20 0.72
▸ TP53 P04637 6/20 0.69
▸ NPC1 O15118 8/20 0.64
▸ RAB9A P51151 8/20 0.64
▸ ALDH1A1 P00352 6/20 0.64
▸ HPGD P15428 5/20 0.64
▸ KDM4E B2RXH2 4/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ NPSR1 Q6W5P4 1/20 0.64
▸ RXFP1 Q9HBX9 1/20 0.64
▸ HTT P42858 1/20 0.63
▸ CASP3 P42574 1/20 0.63
▸ SENP8 Q96LD8 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12963439 0.91 MMP2 (0.74) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL12421981 0.90 MAPT (0.74) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL12963239 0.90 MAPT (0.74) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL2196513 0.89 MAPT (0.64) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL12422009 0.89 MAPT (0.73) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL6483615 0.89 MAPT (0.73) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL2192742 0.89 MAPT (0.73) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL2195081 0.88 MAPT (0.65) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL2245368 0.88 MAPT (0.63) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL2193862 0.88 MAPT (0.63) MMP2MMP9MMP8MMP13SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. (US) 2023-06-15 — — US disclosed
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2018-08-02 — — US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed
EP-2338059-B1 Ligands for aggregated tau molecules WISTA LAB LTD (SG) 2015-04-08 — — EP disclosed
US-8993604-B2 Treatment and prevention of dengue virus infections SIGA TECHNOLOGIES, INC. (US) 2015-03-31 — — US disclosed
US-8895313-B2 Ligands for aggregated tau molecules WISTA LABORATORIES LTD. (SG) 2014-11-25 — — US disclosed
US-8895313-B2 Ligands for aggregated tau molecules WISTA LABORATORIES LTD. (SG) 2014-11-25 — — US disclosed
US-8895313-B2 Ligands for aggregated tau molecules WISTA LABORATORIES LTD. (SG) 2014-11-25 — — US disclosed
CN-102224423-B Ligands for aggregated tau molecules WISTA LABORATORIES LTD. (SG) 2014-10-22 — — CN disclosed
US-20120258079-A1 Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. 2012-10-11 — — US disclosed
CN-102224423-A Ligands for aggregated tau molecules WISTA LAB LTD 2011-10-19 — — CN disclosed
US-20110171739-A1 LIGANDS FOR AGGREGATED TAU MOLECULES WISTA LABORATORIES LTD. 2011-07-14 — — US disclosed
US-20110171739-A1 LIGANDS FOR AGGREGATED TAU MOLECULES WISTA LABORATORIES LTD. 2011-07-14 — — US disclosed
US-20110171739-A1 LIGANDS FOR AGGREGATED TAU MOLECULES WISTA LABORATORIES LTD. 2011-07-14 — — US disclosed
EP-2338059-A1 LIGANDS FOR AGGREGATED TAU MOLECULES Wista Laboratories Ltd. (SG) 2011-06-29 — — EP disclosed
WO-2010034982-A1 LIGANDS FOR AGGREGATED TAU MOLECULES WISTA LABORATORIES LTD. (SG) 2010-04-01 — — WO disclosed
EP-1416931-A1 INHIBITORS OF POLYQ-AGGREGATION Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2004-05-12 — — EP disclosed
WO-2003015772-A1 INHIBITORS OF POLYQ-AGGREGATION MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2003-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 MMP2 3366/4885MMP9 4393/4885MMP8 4303/4885
US-20110171739-A1 LIGANDS FOR AGGREGATED TAU MOLECULES MAPT, PRNP, MAP4 MMP2 4289/4885MMP9 4796/4885MMP8 4843/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN MMP2 3801/4885MMP9 4453/4885MMP8 4548/4885
US-20120258079-A1 Treatment and Prevention of Dengue Virus Infections HAVCR2, TTPA, CHIA MMP2 930/4885MMP9 3628/4885MMP8 2126/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 MMP2 3799/4885MMP9 4443/4885MMP8 4444/4885
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 MMP2 3366/4885MMP9 4393/4885MMP8 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.